2024-11-13 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis Report

**1. Stock Performance and Relative Strength:**

Merck & Co Inc (MRK) is a global pharmaceutical company focused on developing and manufacturing prescription medicines, vaccines, and animal health products. 

* **Cumulative Return (MRK):** 94.04%
* **Cumulative Return (VOO):** 179.25%
* **Cumulative Return Difference:** -85.21%
* **Relative Divergence:** 1.96 (This means MRK's performance is currently in the 96th percentile of its historical range compared to VOO)

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 8.2% | 17.4% | -30.2% | 0.9 | 135.8 |
| 2016-2018  | 59.7% | 17.1% | 27.4% | 0.7 | 184.4 |
| 2017-2019  | 65.0% | 17.1% | 13.3% | 0.7 | 219.5 |
| 2018-2020  | 58.9% | 26.7% | 11.6% | 0.7 | 197.4 |
| 2019-2021  | 16.7% | 26.7% | -83.3% | 0.6 | 193.9 |
| 2020-2022  | 39.4% | 26.7% | 15.8% | 0.5 | 280.7 |
| 2021-2023  | 55.2% | 19.9% | 20.2% | 0.3 | 275.8 |
| 2022-2024  | 38.7% | 24.6% | 8.3% | 0.3 | 254.8 |

* **Alpha:** MRK has exhibited a negative alpha over the past few years, indicating underperformance relative to the market.
* **Beta:** MRK's beta has been steadily decreasing, suggesting it has become less volatile than the market. 

**2. Recent Price Movements:**

* **Closing Price:** 98.58
* **5-Day Moving Average:** 100.83
* **20-Day Moving Average:** 104.14
* **60-Day Moving Average:** 110.9

MRK's price is currently below all three moving averages, indicating a potential downtrend.

**3. Technical Indicators:**

* **RSI:** 23.79 (This indicates that MRK is currently in oversold territory)
* **PPO:** -0.16 (This suggests that the momentum is negative)
* **Delta_Previous_Relative_Divergence:** -25.4 (A negative value suggests that the relative divergence is decreasing, indicating potential downside)
* **Expected Return:** 0.0% (The expected return over the next 2+ years is neutral relative to the S&P 500)

**4. Recent Earnings Performance and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

* **Most Recent Earnings:**  MRK beat analysts' expectations on revenue and EPS for the last quarter (2024-11-06). 
* **Outlook:** MRK continues to demonstrate consistent revenue growth and profitability. Analysts are optimistic about the company's future prospects.

**5. Financial Information Analysis:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

* **Strong Profit Margins:** MRK maintains consistently high profit margins, suggesting efficient operations and strong pricing power.
* **Stable Revenue Growth:**  Revenue is steadily growing, indicating healthy demand for the company's products.

**Capital and Profitability:**

| Quarter  | Equity    | ROE |
|---|---|---|
| 2024-09-30 | $44.50B  | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50%  |

* **Solid Capital Position:**  MRK possesses a substantial amount of equity, indicating a strong financial foundation.
* **ROE Fluctuation:**  ROE has shown fluctuation over the past year, possibly due to factors such as investments or changes in net income.

**6. News and Recent Events:**

* **Earnings Release (2024-11-06):**  The recent earnings release was well-received by analysts, with positive commentary on the company's performance and future outlook. 
* **Market Outlook:** Analysts generally hold a positive view on MRK, highlighting its strong brand recognition, diversified product portfolio, and research and development pipeline.
* **Analyst Opinions:** The majority of analysts have a "Buy" or "Strong Buy" rating on MRK.

**7. Summary and Conclusion:**

MRK is a large-cap pharmaceutical company with a strong market position and a history of solid financial performance. Despite recent underperformance compared to the market, the company shows consistent revenue growth, robust profitability, and a promising future outlook. 

**Technical indicators suggest potential downside in the short term, but the oversold condition and positive earnings news may provide an opportunity for investors with a long-term horizon.**

**Overall, MRK remains a worthwhile investment for investors seeking exposure to the pharmaceutical industry, particularly those seeking long-term growth and stability.**

**Disclaimer:**  This analysis is for informational purposes only and should not be considered as financial advice. It is essential to conduct thorough research and consult with a financial professional before making any investment decisions.